FCMV
THRX

Foresite Capital Management V’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Foresite Capital Management V’s Portfolio THRX Stock Details THRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,108,796
Closed -$16.6M – 6
2023
Q4 		$16.6M Hold
4,108,796
– – 22.67% 2
2023
Q3 		$11.1M Buy
4,108,796
+523,450
+15% +$2.05M 17.63% 3
2023
Q2 		$33.5M Hold
3,585,346
– – 24.43% 2
2023
Q1 		$31.8M Hold
3,585,346
– – 23.54% 2
2022
Q4 		$17.9M Buy
3,585,346
+250,000
+7% +$1.46M 13.87% 4
2022
Q3 		$19.3M Hold
3,335,346
– – 14.87% 2
2022
Q2 		$18.4M Buy
3,335,346
+122,614
+4% +$1.01M 12.89% 2
2022
Q1 		$37M Hold
3,212,732
– – 15.13% 2
2021
Q4 		$40.7M Buy
+3,212,732
New +$48.5M 10.01% 3

Foresite Capital Management V's THRX Position: Q1 2024 in Review

Foresite Capital Management V sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q1 2024, closing a stake of 4,108,796 shares — an estimated $16.6M sold.

Foresite Capital Management V first reported a position in THRX in Q4 2021 and held it in 9 quarters. The position peaked at $40.7M in Q4 2021. 1 fund tracked by Wall St. Rank holds THRX as of Q1 2024.

  • Foresite Capital Management V reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Foresite Capital Management V sold 4,108,796 Theseus Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $16.6M.
  • Foresite Capital Management V first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
  • Foresite Capital Management V's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $40.7M in Q4 2021.
  • 1 fund tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Foresite Capital Management V's 13F filing for Q1 2024, filed 15 May 2024.